PARTING: Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief

This single-arm, open-label trial (n=15) aims to assess the feasibility, acceptability, and safety of Psilocybin-Assisted Supportive Psychotherapy in treating prolonged grief disorder in bereaved cancer carers.

Conducted by the QIMR Berghofer Medical Research Institute in Australia, the study involves three psychotherapy sessions before a psilocybin dosing session and four post-experience integration sessions.

Participants will be closely monitored by trial psychologists and nurses. Rigorous screening will be conducted to ensure eligibility, and baseline and follow-up assessments will measure prolonged grief symptoms. Feasibility, acceptability, and safety will be evaluated through recruitment and retention rates, fidelity to assessments, and adverse event monitoring.

The trial aims to provide an initial impression of efficacy through qualitative analysis of participants’ experiences and changes in grief scores.

The intervention, supported by Woke Pharmaceuticals, involves administering 25 mg of psilocybin orally. Recruitment started on 13th November 2023, with an anticipated completion date of 22nd April 2024.

Topic Palliative Care Depression
Compound Psilocybin
Country Australia
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Woke Pharmaceuticals
Woke Pharmaceuticals is an Australian biotech company developing novel psychedelic compounds.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.